Stock of HCA Healthcare Inc. (HCA) performance and profitability takes another direction

At the time of writing, HCA Healthcare Inc. [HCA] stock is trading at $194.06, up down -2.40%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HCA shares have lost -7.13% over the last week, with a monthly amount drifted -7.70%, and not seem to be holding up well over a long-time horizon.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

On 20, September 2022, HCA Healthcare Presents 2022 HCA Healthcare Awards of Distinction. In a post published today on Yahoo Finance, HCA Healthcare, Inc. (NYSE: HCA), one of the nation’s leading healthcare providers, today presented its annual HCA Healthcare Awards of Distinction to recipients at a ceremony in Nashville. The HCA Healthcare Awards of Distinction—which include the Frist Humanitarian Awards, the Innovators Award and the Excellence in Nursing Awards—are the highest honors HCA Healthcare bestows on employees, physicians and volunteers.

From an analyst’s perspective:

HCA Healthcare Inc. [NYSE: HCA] stock has seen the most recent analyst activity on July 06, 2022, when BMO Capital Markets downgraded its rating to a Underperform and also revised its price target to $160 from $233. Previously, Loop Capital started tracking the stock with Buy rating on June 17, 2022, and set its price target to $240. On May 27, 2022, upgrade upgraded it’s rating to Outperform and revised its price target to $271 on the stock. Wells Fargo started tracking the stock assigning a Equal Weight rating and suggested a price target of $267 on March 29, 2022. JP Morgan downgraded its rating to Neutral for this stock on December 21, 2021, but kept the price target unchanged to $270. In a note dated September 27, 2021, SVB Leerink initiated an Outperform rating and iterated a target price of $320 on this stock.

For the past year, the stock price of HCA Healthcare Inc. fluctuated between $164.47 and $279.02. Currently, Wall Street analysts expect the stock to reach $239.48 within the next 12 months. HCA Healthcare Inc. [NYSE: HCA] shares were valued at $194.06 at the most recent close of the market. An investor can expect a potential return of 23.41% based on the average price forecast.

Analyzing the HCA fundamentals

According to HCA Healthcare Inc. [NYSE:HCA], the company’s sales were 14.82 billion in the recent quarter, which represents an 2.70% jump. Gross Margin for this corporation currently stands at +16.47% with Operating Margin at +16.47%, Pretax Margin comes in at +16.74%, and Net Margin reading is +11.84%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 192.37 points at the first support level, and at 190.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 196.92, and for the 2nd resistance point, it is at 199.79.

HCA Healthcare Inc. [HCA] reported earnings per share of $4.21 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $3.7/share, meaning a difference of $0.51 and a surprise factor of 13.80%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were $4.12 per share as compared to estimates of $4.25 per share, a difference of $-0.13 representing a surprise of -3.10%.

Ratios To Look Out For

It is important to note that HCA Healthcare Inc. [NYSE:HCA] has a current ratio of 1.50. As well, the Quick Ratio is 1.21, while the Cash Ratio is 0.16. Considering the valuation of this stock, the price to sales ratio is 1.44 and the P/E (TTM) ratio is 9.33.

Transactions by insiders

Insider trading has also been a hot topic recently, with 0 insiders purchasing 0 shares and 0 selling 0 shares in the past 3 months. Recent insider trading involved Elcan Patricia F, 10% Owner, that happened on Jul 25 when 325.0 shares were purchased. SVP & Chief Human Res. Officer, Berres Jennifer completed a deal on May 13 to sell 2358.0 shares. Meanwhile, SVP & Chief Ethics Officer Whalen Kathleen M sold 500.0 shares on May 03.